Antengene enters into commercialization partnership with hansoh pharma for first/only-in-class xpo1 inhibitor xpovio®(selinexor) in the mainland of china

-      antengene and hansoh pharma to enter into collaboration agreement involving commercialization of xpovio® in the mainland of china, broadening coverage and improving access of the drug to patients in the mainland of china -      antengene to receive up to rmb200 million in upfront payments, and up to rmb535 million in milestone payments from hansoh pharma -      xpovio® is approved in the mainland of china for relapsed/refractory multiple myeloma. antengene plans to submit supplemental new drug application (snda) for xpovio® as a monotherapy for the treatment of adult patients with relapsed /refractory diffuse large b-cell lymphoma in q3 2023, and in combination for the treatment of adult patients with multiple myeloma who have received at least one prior therapy  in h1 2024 -      recent clinical data presentation showcased broad indication expansion potential in myelofibrosis and endometrial cancer shanghai and hong kong , aug. 10, 2023 /prnewswire/ -- antengene corporation limited ("antengene" sehk: 6996.hk), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hematology and oncology, and hansoh pharmaceutical group company limited ("hansoh pharma" sehk: 3692.hk), a leading innovation-driven pharmaceutical company with a focus on the treatment of major diseases including oncology, infectious diseases, cns disorders, metabolic diseases, and autoimmune diseases, announced today the entrance into a collaboration agreement between antengene and hansoh pharma for the commercialization of xpovio® in the mainland of china.
KPTI Ratings Summary
KPTI Quant Ranking